In October 2007, the FDA declared that the labeling for all PDE5 inhibitors, which includes tadalafil, needs a much more notable warning from the possible danger of sudden hearing decline as the results of post-advertising and marketing reviews of short-term deafness connected to utilization of PDE5 inhibitors.[19][8] The FDA concluded that they ha… Read More